Trial · NCT07350070
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
NCT07350070, Phase 2, Not yet recruiting, Tongji Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension. Trials, record NCT07350070. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07350070
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- NCT number
- NCT07350070
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Tongji Hospital
- Conditions
- HCC, Liver Cirrhosis, Portal Hypertension
- Interventions
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol
- First posted
- 2026-01-20
- Last updated
- 2026-01-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate(ORR) | From the date of enrollment, until the tumor progresses, the patient dies, or the study concludes (whichever occurs first), the assessment period can last up to 60 months. | ORR is defined as the proportion of patients who achieved the best therapeutic response of PR or CR among all the patients enrolled. |
| Secondary | Progression-free survival(PFS) | From the date of enrollment, until the tumor progresses, the patient dies, or the study concludes (whichever occurs first), the assessment period can last up to 60 months. | PFS is defined as the time from study enrollment to the first occurrence of disease progression. |
| Secondary | Overall survival(OS) | From the date of enrollment, until the patient dies, the assessment period can last up to 60 months. | OS is defined as the time from the start of the study enrollment to death. |
| Secondary | Adverse events (AEs) | From the baseline up to 12 months. | AE is defined as any event that occurs during the treatment period and is not related to the purpose of the treatment which assessed by CTCAE v4.0. |
| Secondary | The rate of decompensation of liver cirrhosis | From the date of enrollment, until the patient dies, or the study concludes (whichever occurs first), the assessment period can last up to 60 months. | The definition of decompensated portal hypertension in liver cirrhosis is the occurrence of clinical events such as upper gastrointestinal bleeding, hepatic encephalopathy, and liver function failure during the treatment period. |
| Other | Difference in treatment effect (Hazard Ratio) between participants with emotional disorders versus non-emotional disorders, assessed by the interaction p-value. | From baseline until death, study conclusion, or up to 60 months (whichever occurs first). | To explore the efficacy difference of the quadruple therapy between pre-defined subgroups. The primary efficacy endpoint (e.g., Progression-Free Survival) will be analyzed separately within each subgroup (emotional disorders vs. non-emotional disorders). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07350070
GET https://conductscience.org/api/trials/v1/NCT07350070/registered